Lonza Group AG (LZAGY)
USD 65.07
(-1.2%)
USD 65.07
(-1.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.61 Billion CHF | 40.7% |
| 2022 | 1.85 Billion CHF | -26.68% |
| 2021 | 2.53 Billion CHF | -15.5% |
| 2020 | 2.99 Billion CHF | 0.3% |
| 2019 | 2.98 Billion CHF | -17.56% |
| 2018 | 3.62 Billion CHF | -2.92% |
| 2017 | 3.73 Billion CHF | 137.43% |
| 2016 | 1.57 Billion CHF | 11.1% |
| 2015 | 1.41 Billion CHF | -16.48% |
| 2014 | 1.69 Billion CHF | -24.59% |
| 2013 | 2.24 Billion CHF | -7.5% |
| 2012 | 2.42 Billion CHF | -11.91% |
| 2011 | 2.75 Billion CHF | 202.75% |
| 2010 | 910 Million CHF | -7.05% |
| 2009 | 979 Million CHF | -28.01% |
| 2008 | 1.36 Billion CHF | 0.0% |
| 2007 | 1.36 Billion CHF | 47.35% |
| 2006 | 923 Million CHF | 21.93% |
| 2005 | 757 Million CHF | 9.24% |
| 2004 | 693 Million CHF | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 3.64 Billion CHF | 39.46% |
| 2023 Q2 | 2.46 Billion CHF | 32.67% |
| 2023 FY | 2.61 Billion CHF | 40.7% |
| 2023 Q4 | 2.61 Billion CHF | 6.05% |
| 2022 Q2 | 1.94 Billion CHF | -23.04% |
| 2022 FY | 1.85 Billion CHF | -26.68% |
| 2022 Q4 | 1.85 Billion CHF | -4.73% |
| 2021 Q2 | 2.78 Billion CHF | -6.85% |
| 2021 Q4 | 2.53 Billion CHF | -9.29% |
| 2021 FY | 2.53 Billion CHF | -15.5% |
| 2020 Q4 | 2.99 Billion CHF | -14.11% |
| 2020 Q2 | 3.48 Billion CHF | 16.78% |
| 2020 FY | 2.99 Billion CHF | 0.3% |
| 2019 Q4 | 2.98 Billion CHF | -5.15% |
| 2019 FY | 2.98 Billion CHF | -17.56% |
| 2019 Q2 | 3.14 Billion CHF | -13.09% |
| 2018 Q4 | 3.62 Billion CHF | 10.63% |
| 2018 FY | 3.62 Billion CHF | -2.92% |
| 2018 Q2 | 3.27 Billion CHF | -12.25% |
| 2017 Q4 | 3.73 Billion CHF | 154.09% |
| 2017 FY | 3.73 Billion CHF | 137.43% |
| 2017 Q2 | 1.46 Billion CHF | -6.56% |
| 2016 Q4 | 1.57 Billion CHF | -4.38% |
| 2016 FY | 1.57 Billion CHF | 11.1% |
| 2016 Q2 | 1.64 Billion CHF | 16.2% |
| 2015 Q2 | 1.14 Billion CHF | -32.66% |
| 2015 FY | 1.41 Billion CHF | -16.48% |
| 2015 Q4 | 1.41 Billion CHF | 24.04% |
| 2014 FY | 1.69 Billion CHF | -24.59% |
| 2014 Q4 | 1.69 Billion CHF | -27.06% |
| 2014 Q2 | 2.32 Billion CHF | 3.39% |
| 2013 FY | 2.24 Billion CHF | -7.5% |
| 2013 Q4 | 2.24 Billion CHF | -14.08% |
| 2013 Q2 | 2.61 Billion CHF | 7.66% |
| 2012 Q4 | 2.42 Billion CHF | 17.64% |
| 2012 Q2 | 2.06 Billion CHF | -25.12% |
| 2012 FY | 2.42 Billion CHF | -11.91% |
| 2011 Q2 | 829 Million CHF | -8.9% |
| 2011 Q4 | 2.75 Billion CHF | 232.33% |
| 2011 FY | 2.75 Billion CHF | 202.75% |
| 2010 Q4 | 910 Million CHF | -32.19% |
| 2010 FY | 910 Million CHF | -7.05% |
| 2010 Q2 | 1.34 Billion CHF | 37.08% |
| 2009 FY | 979 Million CHF | -28.01% |
| 2009 Q4 | 979 Million CHF | 0.0% |
| 2009 Q2 | - CHF | -100.0% |
| 2008 FY | 1.36 Billion CHF | 0.0% |
| 2008 Q4 | 1.36 Billion CHF | 0.0% |
| 2007 FY | 1.36 Billion CHF | 47.35% |
| 2006 FY | 923 Million CHF | 21.93% |
| 2005 FY | 757 Million CHF | 9.24% |
| 2004 FY | 693 Million CHF | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 6000.00 USD | -43499900.0% |
| Arrayit Corporation | - USD | -Infinity% |
| Atlantic International Corp. | 1.29 Million USD | -201053.899% |
| Biocept, Inc. | 10.37 Million USD | -25056.627% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 51.3 Million USD | -4986.926% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 61.22 Million USD | -4162.942% |
| HTG Molecular Diagnostics, Inc. | 546.32 Thousand USD | -477638.485% |
| iMD Companies, Inc. | 1.1 Million USD | -236384.589% |
| IDenta Corp. | 428.17 Thousand USD | -609462.423% |
| Interpace Biosciences, Inc. | 4.24 Million USD | -61413.08% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | - USD | -Infinity% |
| Lumos Diagnostics Holdings Limited | - USD | -Infinity% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 278 Thousand USD | -938748.921% |
| NovelStem International Corp. | 3.32 Million USD | -78405.709% |
| Optigenex Inc. | 4.42 Million USD | -58855.512% |
| PharmChem, Inc. | - USD | -Infinity% |
| Proteome Sciences plc | 1.63 Million USD | -159924.525% |
| Response Genetics, Inc | 4.91 Million USD | -52970.354% |
| Rennova Health, Inc. | 359.19 Thousand USD | -726528.86% |
| RushNet, Inc. | 4.25 Million USD | -61277.263% |
| ScreenPro Security Inc. | 249.05 Thousand USD | -1047882.333% |
| Stella Diagnostics Inc. | 798.44 Thousand USD | -326787.021% |
| StageZero Life Sciences Ltd. | 576.38 Thousand USD | -452724.689% |
| Todos Medical Ltd. | 33 Million USD | -7808.851% |